Livia Lamartina

Dr. Livia Lamartina

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2020 in European Journal of Endocrinology
Verified
Journal Article
Closed access
PDF file
LLLivia Lamartina
Livia Lamartina
DHDaria Handkiewicz-Junak
Daria Handkiewicz-Junak
Each year, the proportion of thyroid cancer patients presenting with low-risk disease is increasing. The shift in the landscape of thyroid cancer presentation is forcing clinicians to re-evaluate not only management but also surveillance paradigms. During the follow-up, patients are stratified considering their response to treatment and classified into one of the following response categories: excellent, biochemical incomplete, structural incomplete, or indeterminate. These categories reflect a real-time prognosis and thereby substantially influence and personalise disease management. Although at present, no guideline recommends stopping differentiated thyroid carcinoma (DTC) surveillance at any particular time point, the relatively low prevalence of treatment failures in low-risk patients may prompt early discontinuation of surveillance in this subgroup. Therefore, this debate will present an overview of the controversies surrounding the surveillance of low-risk patients with DTC. Abstract Each year, the proportion of thyroid cancer patients presenting with low-risk disease is increasing. The shift in the landscape of thyroid cancer presentation is forcing clinicians to re-evaluate not only management but also surveillance paradigms. During the follow-up, patients are stratified considering their response to treatment and classified into one of the following response categories: excellent, biochemical incomplete, structural incomplete, or indeterminate. These categories reflect a real-time prognosis and thereby substantially influence and personalise disease management. Although at present, no guideline recommends stopping differentiated thyroid carcinoma (DTC) surveillance at any particular time point, the relatively low prevalence of treatment failures in low-risk patients may prompt early discontinuation of surveillance in this subgroup. Therefore, this debate will present an overview of the controversies surrounding the surveillance of low-risk patients with DTC.

10 January 2015 in Endocrine
Verified
Journal Article
Closed access
PDF file
LLLivia Lamartina
Livia Lamartina
DCDavid S. Cooper
David S. Cooper

23 September 2021 in Cancers
Verified
Journal Article
Open access
PDF file
MKMichele Klain
Michele Klain
EZEmilia Zampella
Emilia Zampella
CNCarmela Nappi
Carmela Nappi
ENEmanuele Nicolai
Emanuele Nicolai
RARaffaele Ambrosio
Raffaele Ambrosio
Alberto CuocoloAlberto Cuocolo
Alberto Cuocolo
The present review provides a description of recent advances in the field of functional imaging that takes advantage of the functional characteristics of thyroid neoplastic cells (such as radioiodine uptake and FDG uptake) and theragnostic approach of differentiated thyroid cancer (DTC). Physical and biological characteristics of available radiopharmaceuticals and their use with state-of-the-art technologies for diagnosis, treatment, and follow-up of DTC patients are depicted. Radioactive iodine is used mostly with a therapeutic intent, while PET/CT with 18F-FDG emerges as a useful tool in the diagnostic management and complements the use of radioactive iodine. Beyond 18F-FDG PET/CT, other tracers including 124I, 18F-TFB and 68Ga-PSMA, and new methods such as PET/MR, might offer new opportunities in selecting patients with DTC for specific imaging modalities or treatments.

9 February 2022 in Medicina
Verified
Journal Article
Open access
PDF file
PPPeteris Prieditis
Peteris Prieditis
MRMaija Radzina
Maija Radzina
MMMadara Mikijanska
Madara Mikijanska
MLMara Liepa
Mara Liepa
KSKaspars Stepanovs
Kaspars Stepanovs
VCVito Cantisani
Vito Cantisani
Background and Objectives: The aim of the study was to evaluate the predictive value of the ultrasound criterion “non-marked hypoechogenicity” for malignancy and to determine whether classification of these nodules as TIRADS 3 could improve the overall accuracy of consequently adjusted M-TIRADS score. Materials and Methods: A total of 767 patients with 795 thyroid nodules were subject to ultrasonography examination and ultrasound-guided fine needle aspiration biopsy. Nodules were classified by Kwak TIRADS and modified (M-TIRADS) categories 4A, 4B, and 5 according to number of suspicious US features (marked hypoechogenicity, microlobulated or irregular margins, microcalcifications, taller-than-wide shape, metastatic lymph nodes). Non-marked hypoechoic nodules were classified as TIRADS 3. Results: Thyroid nodules were classified as TIRADS 2, 3, 4A, 4B, and 5 in 14.5, 57.5, 14.2, 8.1, and 5.7%, respectively. Only histopathologic results (125 nodules underwent surgery) and highly specific cytology results (Bethesda II, VI) were accepted as a standard of reference, forming a sub-cohort of 562/795 nodules (70.7%). Malignancy was found in 7.7%. Overall, M-TIRADS showed sensitivity/specificity of 93.02/81.31%, and for PPV/NPV, these were 29.2/99.29%, respectively (OR—18.62). Irregular margins showed the highest sensitivity and specificity (75.68/93.74%, respectively). In TIRADS 3 category, 37.2% nodules were isoechoic, 6.6% hyperechoic, and 52.2% hypoechoic (there was no difference of malignancy risk in hypoechoic nodules between M-TIRADS and Kwak systems—0.9 vs. 0.8, respectively). Accuracy of M-TIRADS classification in this cohort was 78.26% vs. 48.11% for Kwak. Conclusions: The non-marked hypoechoic nodule pattern correlated with low risk of malignancy; classification of these nodules as TIRADS 3 significantly improved the predictive value and overall accuracy of the proposed M-TIRADS scoring with malignancy risk increase in TIRADS 4 categories by 20%; and no significant alteration of malignancy risk in TIRADS 3 could contribute to reducing overdiagnosis, obviating the need for FNA.

11 October 2014 in Annales d'Endocrinologie
Verified
Journal Article
Closed access
LLLivia Lamartina
Livia Lamartina
DHD. Hartl
D. Hartl
ABA. Berdelou
A. Berdelou
AGA. Al Ghuzlan
A. Al Ghuzlan
IBI. Borget
I. Borget
SLS. Leboulleux
S. Leboulleux

11 October 2014 in Annales d'Endocrinologie
Verified
Journal Article
Closed access
LLLivia Lamartina
Livia Lamartina
SIS. Ippolito
S. Ippolito
ABA. Berdelou
A. Berdelou
AGA. Al Ghuzlan
A. Al Ghuzlan
IBI. Borget
I. Borget
SLS. Leboulleux
S. Leboulleux